VJOncology Podcast

In this week’s VJOncology podcast, we will be covering highlights from ASCO GU 2026 in San Francisco, CA. Dive into the latest advancements in genitourinary cancers, including groundbreaking trial results and emerging treatment strategies. In this episode, join Enrique Gallardo, MD, Parc Taulí University Hospital, Barcelona, Spain, Jan-Jaap Mellema, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, Pooja Ghatalia, MD, Fox Chase Cancer Center, Philadelphia, PA, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and, Aly-Khan Lalani, MD, McMaster University, Hamilton, Canada, as they discuss critical findings from ASCO GU 2026, including combination therapies, innovative approaches to bladder preservation, and novel biomarkers in prostate and renal cell carcinoma.

In this week’s VJOncology podcast, as part of Oesophageal Cancer Awareness Month in the UK, we are pleased to bring you the latest advances shaping the treatment landscape for oesophageal and gastroesophageal cancers. Join leading experts Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, Berend van der Wilk, MD, Erasmus MC Cancer Institute, Kohei Shitara, MD, National Cancer Center Hospital East, and Ian Chau, MD, Royal Marsden Hospital, as they discuss pivotal data from key clinical trials across the disease spectrum. Our expert panel highlights how these data are refining first-line strategies, informing organ-preserving approaches, and advancing biomarker-driven therapies in oesophageal and gastroesophageal cancers.

In this week’s VJOncology podcast, we are delighted to bring you the latest advances in circulating tumor DNA (ctDNA)-informed monitoring and follow-up strategies in breast cancer. Join leading experts Wolfgang Janni, MD, University of Ulm, Ulm, Germany, Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, and Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MA, as they explore cutting-edge data from key studies including SURVIVE, LEADER, a Phase I/II trial of vepdegestrant, and PACE. Together, they discuss the evolving role of circulating tumor DNA in detecting molecular relapse, guiding early intervention strategies, monitoring treatment response, and predicting resistance across early and advanced ER+/HER2-negative and HR+/HER2-negative breast cancer settings.

In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.

In recognition of Cervical Cancer Awareness Month, this episode of VJOncology podcasts explores advances in cervical cancer prevention and treatment. We hear from three leading experts who discuss pivotal developments shaping clinical practice. Dr Domenica Lorusso from Fondazione IRCCS National Cancer Institute of Milan examines the breakthrough combination of immunotherapy and radiotherapy in locally advanced disease, highlighting practice-changing data from the KEYNOTE-A18 trial that established pembrolizumab plus chemoradiotherapy as the new standard of care for stage 3 cervical cancer. Dr Amanda Psyrri from National Kapodistrian University of Athens underscores the critical role of HPV vaccination in preventing not only cervical cancer but also HPV-associated oropharyngeal malignancies, particularly those caused by high-risk subtypes 16 and 18. Finally, Dr Alberto Farolfi from IRCCS Istituto Romagnolo per lo Studio dei Tumori shares real-world evidence on the addition of bevacizumab to pembrolizumab-chemotherapy regimens in advanced cervical cancer, demonstrating survival benefits without increased serious adverse events. This episode offers essential insights into the evolving landscape of cervical cancer management from prevention through advanced disease.